The future of antiinflammatory therapy.
The cells and mediators that make up the inflammatory response have the potential to injure tissues and contribute to the pathophysiology of many inflammatory diseases. Strategies to reduce neutrophil migration into sites of inflammation and subsequent activation by inhibiting integrin-mediated adhesion hold promise for successful treatment of a variety of inflammatory diseases. New pharmacologic agents that specifically target prostanoid mediators of inflammation by specifically inhibiting the activity of cyclooxygenase 2 are potent antiinflammatory agents with fewer gastrointestinal side effects than nonspecific cyclooxygenase inhibitors. These areas of antiinflammatory research are rapidly yielding drugs with diverse future applications in equine medicine.
Jones
S L
SL
Department of Clinical Sciences, College of Veterinary Medicine, North Carolina State University, Raleigh, North Carolina 27606, USA. sam_jones@ncsu.edu
Blikslager
A
A
D000818:Animals; D000893:Anti-Inflammatory Agents / Q000627:therapeutic use*; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000627:therapeutic use; D015815:Cell Adhesion Molecules; D016861:Cyclooxygenase Inhibitors / Q000627:therapeutic use; D006734:Horse Diseases / Q000188:drug therapy*; D006736:Horses; D007249:Inflammation / Q000188:drug therapy / Q000662:veterinary*; D018836:Inflammation Mediators
D000893:Anti-Inflammatory Agents; D000894:Anti-Inflammatory Agents, Non-Steroidal; D015815:Cell Adhesion Molecules; D016861:Cyclooxygenase Inhibitors; D018836:Inflammation Mediators